{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-168973","form_type":"8-K","ticker":"PROK","cik":"0001850270","company_name":"PROKIDNEY CORP.","filed_at":"2023-06-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.226536+00:00","generated_at":"2026-06-13T23:14:09.009860+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"ProKidney to purchase Greensboro, NC manufacturing facility for $25.5M; eligible for $13.3M tax credits","bullets":["Purchase price of ~$25.5M cash for a 210K sq ft facility and 22 acres; expected close by end of June 2023.","Company eligible for up to $13.3M in tax credits from city, county, and state; requires 330+ new jobs by Dec 2028 and ~$458M investment by Dec 2027.","Facility will support commercial manufacturing for REACT cell therapy, currently in Phase 3 trials for diabetic CKD.","Cash as of March 31, 2023 expected to fund operations through interim results from proact 1 trial, anticipated in late 2024.","Company targeting BLA submission for FDA approval in 2026 with potential U.S. commercial launch later that year."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-168973","json":"https://secwatch.observer/filing/0001193125-23-168973.json","markdown":"https://secwatch.observer/filing/0001193125-23-168973.md","text":"https://secwatch.observer/filing/0001193125-23-168973.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850270/000119312523168973/0001193125-23-168973-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850270/000119312523168973/d475847d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T23:14:09.009860+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3439aa4ad3e6d54957c3627564bd3a6d573062c5","claim":"PROKIDNEY CORP. entered into the Agreement with the city of Greensboro, N.C., Guilford County, N.C., and the North Carolina State Economic Investment Committee valued at approximately $25.5 million (effective 2023-06-13).","evidence_excerpt":"On June 13, 2023, ProKidney Corp. (the “Company”) announced its agreement to purchase a 210,000 square foot facility and approximately 22 acres of land in Greensboro, N.C., to support the Company’s future commercial manufacturing needs for REACT ® , its proprietary REnal Autologous Cell Therapy, currently in Phase 3 development for the treatment of diabetic chronic kidney disease.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850270/000119312523168973/0001193125-23-168973-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"the city of Greensboro, N.C., Guilford County, N.C., and the North Carolina State Economic Investment Committee"},{"label":"Value","value":"approximately $25.5 million"},{"label":"Effective","value":"2023-06-13"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}